According to a recent LinkedIn post from Beacon Therapeutics, Professor Szilárd Kiss is scheduled to present data from the company’s DAWN trial of investigational gene therapy laru-zova for X-linked retinitis pigmentosa at the 49th Macula Society Annual Meeting in San Diego. The talk, focused on 9-plus month safety, efficacy and surgical technique data from the Phase 2 trial, is slated for Friday, February 27.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Beacon is advancing laru-zova through mid-stage clinical evaluation in a rare inherited retinal disease with high unmet need. For investors, the dissemination of Phase 2 data at a specialized ophthalmology forum may serve as a catalyst for external validation, shaping expectations around the program’s risk profile and potential progression to later-stage studies.
By highlighting safety and efficacy alongside surgical technique, the update points to both clinical and procedural learning that could influence eventual commercial adoption if the therapy succeeds. Visibility at the Macula Society meeting may also enhance Beacon’s profile among key opinion leaders, which could support future partnering, trial enrollment, and strategic positioning in the gene therapy segment of ophthalmology.